ACM
TGTX icon

AlphaCrest Capital Management’s TG Therapeutics TGTX Stock Holding History

AlphaCrest Capital Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-77,224
Closed -$328K – 1377
2022
Q2 		$328K Sell
77,224
-6,700
-8% -$41.8K 0.02% 1087
2022
Q1 		$798K Buy
83,924
+67,714
+418% +$784K 0.04% 653
2021
Q4 		$308K Buy
+16,210
New +$421K 0.01% 1253
2021
Q3 		– Sell
-27,227
Closed -$1.06M – 1380
2021
Q2 		$1.06M Buy
+27,227
New +$1.07M 0.05% 645
2020
Q4 		– Sell
-12,600
Closed -$337K – 1268
2020
Q3 		$337K Buy
12,600
+1,400
+13% +$32.2K 0.04% 803
2020
Q2 		$218K Sell
11,200
-70,900
-86% -$1.14M 0.04% 797
2020
Q1 		$808K Buy
82,100
+38,000
+86% +$480K 0.1% 360
2019
Q4 		$490K Buy
+44,100
New +$335K 0.04% 798

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AlphaCrest Capital Management's TGTX Position: Q3 2022 in Review

AlphaCrest Capital Management sold out of TG Therapeutics (TGTX) in Q3 2022, closing a stake of 77,224 shares — an estimated $328K sold.

AlphaCrest Capital Management first reported a position in TGTX in Q4 2019 and held it in 8 quarters. The position peaked at $1.06M in Q2 2021. 183 funds tracked by Wall St. Rank hold TGTX as of Q3 2022.

  • AlphaCrest Capital Management reported no remaining TG Therapeutics position as of Q3 2022 after selling out during the quarter.
  • AlphaCrest Capital Management sold 77,224 TG Therapeutics shares in Q3 2022, an estimated $328K.
  • AlphaCrest Capital Management first reported a position in TG Therapeutics in Q4 2019 and held it in 8 quarters.
  • AlphaCrest Capital Management's TG Therapeutics position peaked at $1.06M in Q2 2021.
  • 183 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2022.

Based on AlphaCrest Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.